• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Mar 25;15(1):10343.
doi: 10.1038/s41598-025-94725-4. Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients

Alba Sánchez[SUP] #[/SUP][SUP] 1 2 [/SUP], Graciano García-Pardo[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Anna Martí[SUP] 1 [/SUP], Frederic Gómez-Bertomeu[SUP] 1 2 3 [/SUP], Silvia Chafino[SUP] 1 2 [/SUP], Marta Massanella[SUP] 2 4 [/SUP], Marina Flores-Piñas[SUP] 1 [/SUP], Lídia Cedó[SUP] 5 6 [/SUP], Francesc Vidal[SUP] 1 2 3 [/SUP], Joaquim Peraire[SUP] #[/SUP][SUP] 7 8 9 [/SUP], Anna Rull[SUP] #[/SUP][SUP] 10 11 12 [/SUP]



Affiliations
Free article Abstract

Hypertension is one of the most common risk factors for COVID-19 clinical progression. The identification of plasma biomarkers for anticipating worse clinical outcomes and to better understand the shared mechanisms between hypertension and COVID-19 are needed. A hypothesis-generating study was designed to compare plasma proteomics and metabolomics between 22 hypertensives (HT) and 41 non-hypertensives (nHT) patients with the most unfavorable COVID-19 progression. A total of 43 molecules were significantly differed between HT (n = 22) and nHT (n = 41). Random Forest (RF) analysis identified myo-inositol, gelsolin and phosphatidylcholine (PC) 32:1 as the top molecules for distinguishing between HT and nHT. Plasma myo-inositol and gelsolin were higher (P = 0.03 and P = 0.02, respectively) and plasma PC 32:1 was lower (P = 0.03) in HT compared to nHT. Biological processes like stress response and blood coagulation, along with KEGG pathways including ascorbate and aldarate metabolism (P = 0.021) and linoleic acid metabolism (P = 0.028), were altered in hypertensive patients with the most unfavorable COVID-19 progression. There is a clear link between hypertension and severe COVID-19. Key biological pathways to consider for improving the prognosis and quality of life of hypertensive patients who become infected with SARS-CoV-2 include oxidative stress, ascorbate and aldarate metabolism, lipid metabolism, immune system and inflammation.

Keywords: Biomarkers; COVID-19; Hypertension; Omics.

 
Back
Top Bottom